Cited by 172Treatment of Major DepressionElectroconvulsive Therapy StudiesNeuroscience and Neuropharmacology Research

Ketamine as a Novel Antidepressant: From Synapse to Behavior

Open access
Murrough, J W·2012·Clinical Pharmacology & Therapeutics

Abstract

Recent reports of a rapid antidepressant effect of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, even in treatment-resistant populations, have spurred translational therapeutic and neuroscience research aimed at elucidating ketamine's mechanism of action. This article provides a concise overview of research findings that pertain to the effects of low-dose ketamine at the cellular, neurocircuitry, and behavioral levels and describes an integrated model of the action of ketamine in the treatment of depression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/clpt.2011.244

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Newly discovered fast-acting antidepressant treatments such as ketamine and scopolamine produce effects on mood within hours or days of treatment.

    “If this is correct, then how can newly discovered fast-acting antidepressant treatments such as ketamine83 and scopolamine,84 which produce effects on mood within hours or days of treatment, be accommodated within the model?”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Murrough, J. W.
Affiliations
Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Murrough, J W
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2011-12-28
Volume
91
Issue
2
Pages
303-309
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2072878669
Cited by
172
References
42
Citations by year
2026: 3 · 2025: 2 · 2024: 8 · 2023: 1 · 2022: 6 · 2021: 9 · 2020: 10 · 2019: 13 · 2018: 6 · 2017: 8 · 2016: 20 · 2015: 26 · 2014: 14 · 2013: 26 · 2012: 19
FWCI
2.40
Type
journal article
Language
en
Open access
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (K23MH094707)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
ketamine, antidepressant mechanism, depression, treatment-resistant depression, NMDA receptor antagonism, glutamate, synapses, neurocircuitry, low-dose ketamine, rapid antidepressant effects
MeSH terms
Animals, Antidepressive Agents, Brain, Clinical Trials as Topic, Disease Models, Animal, Humans, Ketamine, Neural Pathways, Synaptic Transmission, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review